Document is current
Any future updates will be listed below
-
Authors
Marlin, Romain https://orcid.org/0000-0001-8932-0171
Desjardins, Delphine https://orcid.org/0000-0002-5820-3914
Contreras, Vanessa
Lingas, Guillaume
Solas, Caroline
Roques, Pierre https://orcid.org/0000-0003-1825-1054
Naninck, Thibaut https://orcid.org/0000-0002-6261-6412
Pascal, Quentin
Behillil, Sylvie
Maisonnasse, Pauline https://orcid.org/0000-0002-0555-207X
Lemaitre, Julien
Kahlaoui, Nidhal
Delache, Benoit
Pizzorno, Andrés https://orcid.org/0000-0002-0918-6804
Nougairede, Antoine https://orcid.org/0000-0001-7729-2636
Ludot, Camille
Terrier, Olivier https://orcid.org/0000-0001-9393-7684
Dereuddre-Bosquet, Nathalie https://orcid.org/0000-0001-6682-6313
Relouzat, Francis
Chapon, Catherine
Ho Tsong Fang, Raphael
van der Werf, Sylvie https://orcid.org/0000-0002-1148-4456
Rosa Calatrava, Manuel
Malvy, Denis
de Lamballerie, Xavier https://orcid.org/0000-0001-7895-2720
Guedj, Jeremie https://orcid.org/0000-0002-5534-5482
Le Grand, Roger https://orcid.org/0000-0002-4928-4484
- License Information
-
More Information
Article History
Received: 17 March 2022
Accepted: 5 August 2022
First Online: 30 August 2022
Competing interests
: The funders had no role in study design, data collection, data analysis, data interpretation, or data reporting. The authors D.M., C.S., J.G., and X.d.L. report ongoing collaborations between their institution, INSERM, and Toyama, the manufacturer of Favipiravir. The remaining authors declare no competing interests.
